<!DOCTYPE html>

<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head><meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width,initial-scale=1" name="viewport"/>
<link href="/xmlui/themes/Mirage2/images/favicon.ico" rel="shortcut icon"/>
<link href="/xmlui/themes/Mirage2/images/apple-touch-icon.png" rel="apple-touch-icon"/>
<meta content="DSpace 5.8" name="Generator"/>
<link href="https://fonts.googleapis.com/css?family=PT+Sans:400,700|Ubuntu:400,500,700italic|Droid+Sans:400,700" rel="stylesheet" type="text/css"/>
<link href="/xmlui/themes/Mirage2/styles/main.css" rel="stylesheet"/>
<link href="https://papyrus.bib.umontreal.ca:443/xmlui/description.xml" rel="search" title="DSpace" type="application/opensearchdescription+xml"/>
<script>
                //Clear default text of emty text areas on focus
                function tFocus(element)
                {
                if (element.value == ''){element.value='';}
                }
                //Clear default text of emty text areas on submit
                function tSubmit(form)
                {
                var defaultedElements = document.getElementsByTagName("textarea");
                for (var i=0; i != defaultedElements.length; i++){
                if (defaultedElements[i].value == ''){
                defaultedElements[i].value='';}}
                }
                //Disable pressing 'enter' key to submit a form (otherwise pressing 'enter' causes a submission to start over)
                function disableEnterKey(e)
                {
                var key;

                if(window.event)
                key = window.event.keyCode;     //Internet Explorer
                else
                key = e.which;     //Firefox and Netscape

                if(key == 13)  //if "Enter" pressed, then disable!
                return false;
                else
                return true;
                }
            </script><!--[if lt IE 9]>
                <script src="/xmlui/themes/Mirage2/vendor/html5shiv/dist/html5shiv.js">¬†</script>
                <script src="/xmlui/themes/Mirage2/vendor/respond/respond.min.js">¬†</script>
                <![endif]--><script src="/xmlui/themes/Mirage2/vendor/modernizr/modernizr.js">¬†</script><script src="https://www.bib.umontreal.ca/modele/urgence-udem/1.0.0/urgence-udem.js"></script>
<title>Cancer de la prostate r√©sistant √† la castration m√©tastatique : utilisation des nouveaux traitements dans un contexte r√©el au Qu√©bec</title>
<meta content="Dr8axyf94eWBJ8HQjNW4eKxTumAAPsNbvRwpJYMbgGs" name="google-site-verification"/>
<link href="http://purl.org/dc/terms/" rel="schema.DCTERMS">
<link href="http://purl.org/dc/elements/1.1/" rel="schema.DC">
<meta content="Dragomir, Elena Alice" name="DC.contributor">
<meta content="Perreault, Sylvie" name="DC.contributor">
<meta content="Lahcene, Halima" name="DC.creator">
<meta content="2017-10-24T15:23:47Z" name="DCTERMS.dateAccepted" scheme="DCTERMS.W3CDTF">
<meta content="MONTHS_WITHHELD:60" name="DCTERMS.available" scheme="DCTERMS.W3CDTF" xml:lang="fr">
<meta content="2017-10-24T15:23:47Z" name="DCTERMS.available" scheme="DCTERMS.W3CDTF">
<meta content="2017-10-03" name="DCTERMS.issued" scheme="DCTERMS.W3CDTF"/>
<meta content="2017-04" name="DC.date" scheme="DCTERMS.W3CDTF"/>
<meta content="http://hdl.handle.net/1866/19454" name="DC.identifier" scheme="DCTERMS.URI"/>
<meta content="Cancer de la prostate r√©sistant √† la castration m√©tastatique" name="DC.subject" xml:lang="fr"/>
<meta content="Abiraterone" name="DC.subject" xml:lang="fr"/>
<meta content="Docetaxel" name="DC.subject" xml:lang="fr"/>
<meta content="Enzalutamide" name="DC.subject" xml:lang="fr"/>
<meta content="Th√©rapie osseuse" name="DC.subject" xml:lang="fr"/>
<meta content="√âtude en contexte r√©el" name="DC.subject" xml:lang="fr"/>
<meta content="Usage des m√©dicaments" name="DC.subject" xml:lang="fr"/>
<meta content="Metastatic castration-resistant prostate cancer" name="DC.subject" xml:lang="fr"/>
<meta content="Bone-targeted therapy" name="DC.subject" xml:lang="fr"/>
<meta content="Real-world study" name="DC.subject" xml:lang="fr"/>
<meta content="Drug utilization" name="DC.subject" xml:lang="fr"/>
<meta content="Health Sciences - Oncology / Sciences de la sant√© - Oncologie (UMI : 0992)" name="DC.subject" xml:lang="fr"/>
<meta content="Cancer de la prostate r√©sistant √† la castration m√©tastatique : utilisation des nouveaux traitements dans un contexte r√©el au Qu√©bec" name="DC.title" xml:lang="fr"/>
<meta content="Th√®se ou m√©moire / Thesis or Dissertation" name="DC.type"/>
<meta content="Introduction : Depuis 2004, la chimioth√©rapie √† base de docetaxel est la pierre angulaire dans le traitement du cancer de la prostate r√©sistant √† la castration m√©tastatique (CPRCm). √Ä partir de 2011, d‚Äôautres alternatives th√©rapeutiques ont √©t√© approuv√©es par Sant√© Canada pour ces patients, comme l‚Äôabiraterone et l‚Äôenzalutamide pour utilisation apr√®s le docetaxel et plus r√©cemment pour utilisation avant docetaxel (depuis 2013). L‚Äôobjectif primaire de ce projet √©tait de d√©crire l‚Äôusage du docetaxel, de l‚Äôabiraterone (et de l‚Äôenzalutamide) au Qu√©bec et ses d√©terminants. L‚Äôobjectif secondaire √©tait de d√©crire l‚Äôusage des th√©rapies osseuses (le d√©nosumab et l‚Äôacide zol√©dronique) chez les patients souffrant du CPRCm et ses d√©terminants.
M√©thodes : Une √©tude de cohorte r√©trospective descriptive a √©t√© men√©e. Les patients trait√©s pour le cancer de la prostate entre le 1e janvier 2010 et le 30 juin 2014 dans deux h√¥pitaux acad√©miques de l‚ÄôUniversit√© McGill ont √©t√© s√©lectionn√©s √† partir de leurs registres des cancers. Par la suite, les patients atteints de CPRCm ont √©t√© s√©lectionn√©s. Des informations g√©n√©rales et d√©mographiques ainsi que des informations pr√©cises sur la phase du CPRCm et ses traitements ont √©t√© collig√©es √† partir des dossiers m√©dicaux des patients jusqu‚Äôau 10 mai 2016. La cohorte √† l‚Äô√©tude a √©t√© divis√©e en deux groupes selon la p√©riode de diagnostic du CPRCm. La date de l‚Äôajout de l‚Äôabiraterone (et du d√©nosumab) √† la liste de m√©dicaments d‚Äôexception rembours√©s par le r√©gime g√©n√©ral d‚Äôassurance m√©dicaments du Qu√©bec (le 1e f√©vrier 2012) a √©t√© utilis√©e comme date de coupure. Des statistiques descriptives ont √©t√© utilis√©es pour d√©crire l‚Äôutilisation du docetaxel, de l‚Äôabiraterone, de l‚Äôenzaluatamide, du d√©nosumab et de l‚Äôacide zol√©dronique. La m√©thode de Kaplan-Meier et le test du Logrank ont √©t√© utilis√©s pour estimer le temps jusqu‚Äô√† avoir une premi√®re ordonnance du docetaxel et des th√©rapies osseuses. Par ailleurs, la r√©gression multivari√©e de Cox a permis d‚Äôidentifier les d√©terminants de l‚Äôusage du docetaxel, de l‚Äôabiraterone (ou de l‚Äôenzalutamide) et des th√©rapies osseuses.
R√©sultats : Dans notre cohorte, 308 patients atteints du CPRCm ont √©t√© s√©lectionn√©s avec 162 patients (53 %) diagnostiqu√©s avec le CPRCm avant le 1e f√©vrier 2012 et 146 patients (47 %) diagnostiqu√©s avec le CPRCm apr√®s le 1e f√©vrier 2012. L‚Äô√¢ge
ii
m√©dian au diagnostic du CPRCm √©tait de 74,0 ans. Globalement, 82 % des patients diagnostiqu√©s avant 2012 ont eu docetaxel, 53 % ont eu abiraterone et 54% ont eu abiraterone ou enzalutamide comparativement √† 53 %, 74 % et 86 %, respectivement, de ceux diagnostiqu√©s apr√®s 2012. Les d√©terminants de l‚Äôusage global du docetaxel √©taient la pr√©sence de m√©tastases (osseuses et ganglionnaires, et visc√©rales) au diagnostic du CPRC, la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm, avoir moins que 80 ans au diagnostic du CPRCm, √™tre diagnostiqu√© avec le CPRCm avant 2012 et √™tre symptomatique au diagnostic du CPRCm. Les d√©terminants de l‚Äôusage de l‚Äôabiraterone (ou de l‚Äôenzalutamide) √©taient la pr√©sence de m√©tastases (osseuses, ganglionnaires, et visc√©rales) au diagnostic du CPRC, la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm, avoir plus que 80 ans au diagnostic du CPRCm, √™tre diagnostiqu√© avec le CPRCm apr√®s 2012 et avoir des comorbidit√©s cardiaques ou chroniques au diagnostic du CPRCm. Le temps m√©dian avant une premi√®re ordonnance du docetaxel √©tait retard√© de six mois chez les patients diagnostiqu√©s apr√®s 2012 par rapport √† ceux diagnostiqu√©s avant 2012 (p=0,0001). Parmi les patients ayant des m√©tastases osseuses, 82 % ont eu au moins une ordonnance d‚Äôune th√©rapie osseuse (le d√©nosumab ou l‚Äôacide zol√©dronique). Les d√©terminants de l‚Äôusage des th√©rapies osseuses √©taient d‚Äôavoir des m√©tastases osseuses, d‚Äô√™tre diagnostiqu√© avec le CPRCm apr√®s 2012 et d‚Äô√™tre symptomatique au diagnostic du CPRCm.
Conclusion : L‚Äôintroduction de abiraterone (et de l‚Äôenzalutamide) a r√©duit l‚Äôutilisation globale du docetaxel et a prolong√© le temps jusqu‚Äô√† recevoir une ordonnance de celui-ci. Les d√©terminants de l‚Äôusage de ces traitements √©taient l‚Äô√©tendue des m√©tastases, l‚Äô√¢ge au diagnostic du CPRCm, la p√©riode du diagnostic du CPRCm et la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm. Par ailleurs, une proportion significative des patients avec un CPRCm a re√ßu une ordonnance d‚Äôune th√©rapie osseuse." name="DCTERMS.abstract" xml:lang="fr"/>
<meta content="Introduction: Since 2004, docetaxel-based chemotherapy has been the cornerstone of the management of metastatic castration-resistant prostate cancer (mCRPC). The therapeutic arsenal expanded in 2011 to involve several alternative drugs such as abiraterone and enzalutamide for use in docetaxel-refractory patients and then in docetaxel-na√Øve ones (since 2013). This study aimed to describe docetaxel, abiraterone (and enzalutamide) use and its associated factors in Quebec. It also aimed to describe bone-targeted therapy (denosumab and zoledronic acid) utilization and its associated factors in mCRPC patients. Methods: A retrospective cohort study was conducted in two of the main McGill University hospitals. Hospital-based cancer registries were used to identify patients treated for prostate cancer in medical oncology departments between January 1, 2010 and June 30, 2014. Then patients with mCRPC were selected. Patients‚Äô medical charts were reviewed and mCRPC clinical data and treatments were extracted until May 10, 2016. The cohort was divided into two groups according to mCRPC diagnosis period. The cutoff date chosen was February 1, 2012 as it corresponded to the public reimbursement of abiraterone (and denosumab) in Quebec. Descriptive statistics were used to describe docetaxel, abiraterone, enzalutamide, and bone-targeted therapy (denosumab and zoledronic acid) utilization. The Kaplan-Meier method and log-rank test were used to estimate time to receive a first prescription for docetaxel and bone-targeted therapy since mCRPC diagnosis. Cox regression was used to identify predictive factors of docetaxel, abiraterone (or enzalutamide), and bone-targeted therapy use. Results: In our cohort, 308 patients with mCRPC were selected with 162 patients (53%) diagnosed with mCRPC before February 1, 2012 (pre-2012 group) and 146 (47%) diagnosed with mCRPC after February 1, 2012 (post-2012 group). The median age at mCRPC was 74.0 years old. In the pre-2012 group, patients received following treatments: docetaxel 82%, abiraterone 53%, and abiraterone or enzalutamide 54% versus 53%, 74% and 86%, respectively, in the post-2012 group. Factors associated with docetaxel use were having metastases (bone and lymph nodes, and visceral) at CRPC diagnosis, referral to an oncologist before mCRPC development, being younger than 80 at mCRPC diagnosis, having symptoms at mCRPC diagnosis and being diagnosed with mCRPC before 2012. Factors associated with abiraterone (or enzalutamide) use were having metastases (bone, lymph nodes, and visceral) at CRPC diagnosis, referral to an oncologist before mCRPC development, being older than 80 at mCRPC diagnosis, having cardiac or chronic comorbidites at mCRPC diagnosis and being diagnosed with mCRPC after 2012. The median time to have a prescription for docetaxel was delayed by six months in patients diagnosed after 2012 comparatively to those diagnosed before 2012 (p=0.0001). Among patients with bone metastases, 82% had at least one prescription for a bone-targeted therapy (denosumab or zoledronic acid). Factors associated with bone-targeted therapy use were having bone metastases at CRPC diagnosis, being diagnosed with mCRPC after 2012 and having symptoms at mCRPC diagnosis.
Conclusion: The introduction of abiraterone (and enzalutamide) reduced overall docetaxel utilization and delayed time to its initiation. Metastases extent, age, moment of diagnosis with mCRPC, and referral to an oncologist before mCRPC development were the predictive factors either docetaxel, abiraterone or enzalutamide utilization. Patients with mCRPC benefit from bone-targeted therapy (denosumab or zoledronic acid) for bone metastases." name="DCTERMS.abstract" xml:lang="fr"/>
<meta content="fra" name="DCTERMS.language" xml:lang="fr"/>
<meta content="Cancer de la prostate r√©sistant √† la castration m√©tastatique; Abiraterone; Docetaxel; Enzalutamide; Th√©rapie osseuse; √âtude en contexte r√©el; Usage des m√©dicaments; Metastatic castration-resistant prostate cancer; Bone-targeted therapy; Real-world study; Drug utilization; Health Sciences - Oncology / Sciences de la sant√© - Oncologie (UMI : 0992); Th√®se ou m√©moire / Thesis or Dissertation; Sciences pharmaceutiques" name="citation_keywords"/>
<meta content="Cancer de la prostate r√©sistant √† la castration m√©tastatique : utilisation des nouveaux traitements dans un contexte r√©el au Qu√©bec" name="citation_title"/>
<meta content="fra" name="citation_language"/>
<meta content="Lahcene, Halima" name="citation_author"/>
<meta content="https://papyrus.bib.umontreal.ca/xmlui/bitstream/1866/19454/2/Lahcene_Halima_2017_memoire.pdf" name="citation_pdf_url"/>
<meta content="2017-10-03" name="citation_date"/>
<meta content="https://papyrus.bib.umontreal.ca/xmlui/handle/1866/19454" name="citation_abstract_html_url"/>
<script type="text/x-mathjax-config">
                    MathJax.Hub.Config({
                      tex2jax: {
                        inlineMath: [['\\(','\\)']],
                        ignoreClass: "detail-field-data|detailtable|exception"
                      },
                      TeX: {
                        Macros: {
                          AA: '{\\mathring A}'
                        }
                      }
                    });
                </script><script src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML" type="text/javascript">¬†</script>
</meta></meta></meta></meta></meta></meta></link></link></head><body>
<header>
<div class="navbar navbar-default navbar-static-top" role="navigation">
<div class="container">
<div class="hidden-xs hidden-sm hidden-md" id="um-bandeau" role="banner">
<nav class="um-nav um-nav-hidden" role="navigation">
<span class="hidden">Liens externes</span>
<ul>
<li>
<a href="https://www.umontreal.ca/#udemwww-search-personne">Directories</a>
</li>
<li>
<a href="http://www.umontreal.ca/repertoires/facultes.html">Faculties</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/">Libraries</a>
</li>
<li>
<a href="http://plancampus.umontreal.ca/">Campus maps</a>
</li>
<li>
<a href="http://www.umontreal.ca/index/az.html">Sites A to Z</a>
</li>
<li>
<a>My UdeM</a>
<ul>
<li>
<a href="https://monudem.umontreal.ca/">My UdeM Portal</a>
</li>
<li>
<a href="https://outlook.umontreal.ca">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
</ul>
</li>
</ul>
</nav>
<form action="https://google.com/cse" class="um-recherche" id="um-recherche" role="search">
<input name="cx" type="hidden" value="011926736769028447783:qlpu3so2kqq"/><input name="ie" type="hidden" value="ISO-8859-1"/><label class="hidden" for="um-boite-recherche">Search in : </label><span class="um-boite-bouton"><input class="um-boite" id="um-boite-recherche" maxlength="255" name="q" placeholder="UdeM" title="Type your search text" type="text" value=""/><input alt="Search in : " class="um-bouton" src="/xmlui/themes/Mirage2/images/bib-umontreal/loupe.gif" type="image"/></span>
</form>
</div>
<div class="hidden-xs hidden-sm visible-md visible-lg" id="papyrus-deco">
<img alt="Dessin du pavillon Roger Gaudry/Sketch of Roger Gaudry Building" border="0" height="89px" src="/xmlui/themes/Mirage2/images/UdeM.gif" title="Dessin du pavillon Roger Gaudry/Sketch of Roger Gaudry Building" width="193px"/></div>
<div class="navbar-header">
<button class="navbar-toggle" data-toggle="offcanvas" type="button"><span class="sr-only">Toggle navigation</span><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button><a class="navbar-brand hidden-xs hidden-sm visible-md visible-lg um-logo-md-lg" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a><a class="navbar-brand hidden-xs visible-sm hidden-md hidden-lg um-logo-sm" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a><a class="navbar-brand visible-xs hidden-sm hidden-md hidden-lg um-logo-xs" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a>
<div class="navbar-brand separateur visible-xs hidden-sm hidden-md hidden-lg um-sep-site-xs"></div>
<div class="navbar-brand separateur hidden-xs visible-sm hidden-md hidden-lg um-sep-site-sm"></div>
<div class="navbar-brand separateur visible-md visible-lg hidden-xs hidden-sm um-sep-site-md-lg"></div>
<div class="navbar-brand visible-md visible-lg hidden-xs hidden-sm um-titre-site-md-lg">
<span class="papyrus-signature">Papyrus</span> :
                                Institutional Repository</div>
<div class="navbar-brand hidden-xs visible-sm hidden-md hidden-lg um-titre-site-sm">
<span class="papyrus-signature">Papyrus</span>
<br/>Institutional Repository</div>
<div class="navbar-brand visible-xs hidden-sm hidden-md hidden-lg um-titre-site-xs">
<span class="papyrus-signature">Papyrus</span>
</div>
<div class="navbar-header pull-right visible-xs hidden-sm hidden-md hidden-lg">
<ul class="nav nav-pills pull-left">
<li class="dropdown" id="ds-language-selection-xs">
<button class="dropdown-toggle navbar-toggle navbar-link" data-toggle="dropdown" href="#" id="language-dropdown-toggle-xs" role="button"><b aria-hidden="true" class="visible-xs glyphicon glyphicon-globe"></b></button>
<ul aria-labelledby="language-dropdown-toggle-xs" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=fr&amp;show=full">fran√ßais</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
<li>
<form action="/xmlui/login" method="get" style="display: inline">
<button class="navbar-toggle navbar-link"><b aria-hidden="true" class="visible-xs glyphicon glyphicon-user"></b></button>
</form>
</li>
</ul>
</div>
</div>
<div class="navbar-header pull-right hidden-xs">
<div class="nav-language-and-login-lg hidden-xs hidden-sm hidden-md">
<ul class="nav navbar-nav pull-right">
<li class="dropdown" id="ds-language-selection">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="language-dropdown-toggle" role="button"><span class="hidden-xs">English¬†<b class="caret"></b></span></a>
<ul aria-labelledby="language-dropdown-toggle" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=fr&amp;show=full">fran√ßais</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
</ul>
<ul class="nav navbar-nav pull-right">
<li>
<a href="/xmlui/login"><span class="hidden-xs">Login</span></a>
</li>
</ul>
</div>
<div class="hidden-lg">
<ul class="nav navbar-nav pull-right">
<li class="dropdown" id="ds-language-selection">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="language-dropdown-toggle" role="button"><span class="hidden-xs">English¬†<b class="caret"></b></span></a>
<ul aria-labelledby="language-dropdown-toggle" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=fr&amp;show=full">fran√ßais</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/19454?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
</ul>
<ul class="nav navbar-nav pull-right">
<li>
<a href="/xmlui/login"><span class="hidden-xs">Login</span></a>
</li>
</ul>
</div>
<button class="navbar-toggle visible-sm" data-toggle="offcanvas" type="button"><span class="sr-only">Toggle navigation</span><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button>
</div>
</div>
</div>
</header>
<div class="trail-wrapper hidden-print">
<div class="container">
<div class="row">
<div class="col-xs-12">
<div class="breadcrumb dropdown visible-xs">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="trail-dropdown-toggle" role="button">View Item¬†<b class="caret"></b></a>
<ul aria-labelledby="trail-dropdown-toggle" class="dropdown-menu" role="menu">
<li role="presentation">
<a href="/xmlui/" role="menuitem"><i aria-hidden="true" class="glyphicon glyphicon-home"></i>¬† Home</a>
</li>
<li role="presentation">
<a href="/xmlui/handle/1866/2925" role="menuitem">Facult√© de pharmacie</a>
</li>
<li role="presentation">
<a href="/xmlui/handle/1866/2969" role="menuitem">Facult√© de pharmacie ‚Äì Th√®ses et m√©moires</a>
</li>
<li class="disabled" role="presentation">
<a href="#" role="menuitem">View Item</a>
</li>
</ul>
</div>
<ul class="breadcrumb hidden-xs">
<li>
<i aria-hidden="true" class="glyphicon glyphicon-home"></i>¬† <a href="/xmlui/">Home</a>
</li>
<li>
<a href="/xmlui/handle/1866/2925">Facult√© de pharmacie</a>
</li>
<li>
<a href="/xmlui/handle/1866/2969">Facult√© de pharmacie ‚Äì Th√®ses et m√©moires</a>
</li>
<li class="active">View Item</li>
</ul>
</div>
</div>
</div>
</div>
<div class="hidden" id="no-js-warning-wrapper">
<div id="no-js-warning">
<div class="notice failure">JavaScript is disabled for your browser. Some features of this site may not work without it.</div>
</div>
</div>
<div class="container" id="main-container">
<div class="row row-offcanvas row-offcanvas-left">
<div class="horizontal-slider clearfix">
<div class="col-xs-6 col-sm-3 sidebar-offcanvas" id="sidebar" role="navigation">
<div class="word-break hidden-print" id="ds-options">
<div class="ds-option-set" id="ds-search-option">
<form action="/xmlui/discover" class="" id="ds-search-form" method="post">
<fieldset>
<div class="input-group">
<input class="ds-text-field form-control" name="query" placeholder="Search" type="text"/><span class="input-group-btn"><button class="ds-button-field btn" title="Go"><span aria-hidden="true" class="glyphicon glyphicon-search"></span></button></span>
</div>
<div class="radio">
<label><input checked="" id="ds-search-form-scope-all" name="scope" type="radio" value=""/>Search Papyrus</label>
</div>
<div class="radio">
<label><input id="ds-search-form-scope-container" name="scope" type="radio" value="1866/2969"/>Search this Collection</label>
</div>
</fieldset>
</form>
</div>
<h2 class="ds-option-set-head h6">My Account</h2>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_account">
<div class="list-group-item ds-option details_Papyrus" id="aspect_eperson_Navigation_item_details_Papyrus">To submit an item or subscribe to email alerts.</div>
<div class="list-group-item ds-option">
<span class="bold"><a href="/xmlui/login">Login</a></span>
</div>
<a class="list-group-item ds-option" href="/xmlui/register">New user?</a>
</div>
<h2 class="ds-option-set-head h6">Browse</h2>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_browse">
<a class="list-group-item active"><span class="h5 list-group-item-heading h5">All of Papyrus</span></a><a class="list-group-item ds-option" href="/xmlui/community-list">Communities and Collections</a><a class="list-group-item ds-option" href="/xmlui/browse?type=title">Titles</a><a class="list-group-item ds-option" href="/xmlui/browse?type=dateissued">Issue Dates</a><a class="list-group-item ds-option" href="/xmlui/browse?type=author">Authors</a><a class="list-group-item ds-option" href="/xmlui/browse?type=advisor">Advisors</a><a class="list-group-item ds-option" href="/xmlui/browse?type=subject">Subjects</a><a class="list-group-item ds-option" href="/xmlui/browse?type=discipline">Disciplines</a><a class="list-group-item ds-option" href="/xmlui/browse?type=affiliation">Affiliation</a><a class="list-group-item ds-option" href="/xmlui/browse?type=titleindex">Titles index</a><a class="list-group-item active"><span class="h5 list-group-item-heading h5">This Collection</span></a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=title">Titles</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=dateissued">Issue Dates</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=author">Authors</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=advisor">Advisors</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=subject">Subjects</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=discipline">Disciplines</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=affiliation">Affiliation</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2969/browse?type=titleindex">Titles index</a>
</div>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_context"></div>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_administrative"></div>
<div class="list-group" id="aspect_discovery_Navigation_list_discovery"></div>
<h2 class="ds-option-set-head h6">Statistics</h2>
<div class="list-group" id="aspect_statistics_Navigation_list_statistics">
<a class="list-group-item ds-option" href="/xmlui/handle/1866/19454/statistics">View Usage Statistics</a>
</div>
</div>
</div>
<div class="col-xs-12 col-sm-12 col-md-9 main-content">
<div>
<div class="ds-static-div primary" id="aspect_artifactbrowser_ItemViewer_div_item-view">
<p class="ds-paragraph item-view-toggle item-view-toggle-top">
<span class="item-view-toggle"><a href="/xmlui/handle/1866/19454">Show item record</a></span>
</p>
<!-- External Metadata URL: cocoon://metadata/handle/1866/19454/mets.xml-->
<h2 class="page-header first-page-header">Cancer de la prostate r√©sistant √† la castration m√©tastatique : utilisation des nouveaux traitements dans un contexte r√©el au Qu√©bec</h2>
<div class="ds-table-responsive">
<table class="ds-includeSet-table detailtable table table-striped table-hover">
<tr class="ds-table-row odd">
<td class="label-cell">dc.contributor.advisor</td><td class="word-break">Dragomir, Elena Alice</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.contributor.advisor</td><td class="word-break">Perreault, Sylvie</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.contributor.author</td><td class="word-break">Lahcene, Halima</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.accessioned</td><td class="word-break">2017-10-24T15:23:47Z</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.date.available</td><td class="word-break">MONTHS_WITHHELD:60</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.available</td><td class="word-break">2017-10-24T15:23:47Z</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.date.issued</td><td class="word-break">2017-10-03</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.submitted</td><td class="word-break">2017-04</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.identifier.uri</td><td class="word-break">http://hdl.handle.net/1866/19454</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Cancer de la prostate r√©sistant √† la castration m√©tastatique</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Abiraterone</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Docetaxel</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Enzalutamide</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Th√©rapie osseuse</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">√âtude en contexte r√©el</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Usage des m√©dicaments</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Metastatic castration-resistant prostate cancer</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Bone-targeted therapy</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Real-world study</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Drug utilization</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject.other</td><td class="word-break">Health Sciences - Oncology / Sciences de la sant√© - Oncologie (UMI : 0992)</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.title</td><td class="word-break">Cancer de la prostate r√©sistant √† la castration m√©tastatique : utilisation des nouveaux traitements dans un contexte r√©el au Qu√©bec</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.type</td><td class="word-break">Th√®se ou m√©moire / Thesis or Dissertation</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">etd.degree.discipline</td><td class="word-break">Sciences pharmaceutiques</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">etd.degree.grantor</td><td class="word-break">Universit√© de Montr√©al</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">etd.degree.level</td><td class="word-break">Ma√Ætrise / Master's</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">etd.degree.name</td><td class="word-break">M. Sc.</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dcterms.abstract</td><td class="word-break">Introduction : Depuis 2004, la chimioth√©rapie √† base de docetaxel est la pierre angulaire dans le traitement du cancer de la prostate r√©sistant √† la castration m√©tastatique (CPRCm). √Ä partir de 2011, d‚Äôautres alternatives th√©rapeutiques ont √©t√© approuv√©es par Sant√© Canada pour ces patients, comme l‚Äôabiraterone et l‚Äôenzalutamide pour utilisation apr√®s le docetaxel et plus r√©cemment pour utilisation avant docetaxel (depuis 2013). L‚Äôobjectif primaire de ce projet √©tait de d√©crire l‚Äôusage du docetaxel, de l‚Äôabiraterone (et de l‚Äôenzalutamide) au Qu√©bec et ses d√©terminants. L‚Äôobjectif secondaire √©tait de d√©crire l‚Äôusage des th√©rapies osseuses (le d√©nosumab et l‚Äôacide zol√©dronique) chez les patients souffrant du CPRCm et ses d√©terminants.
M√©thodes : Une √©tude de cohorte r√©trospective descriptive a √©t√© men√©e. Les patients trait√©s pour le cancer de la prostate entre le 1e janvier 2010 et le 30 juin 2014 dans deux h√¥pitaux acad√©miques de l‚ÄôUniversit√© McGill ont √©t√© s√©lectionn√©s √† partir de leurs registres des cancers. Par la suite, les patients atteints de CPRCm ont √©t√© s√©lectionn√©s. Des informations g√©n√©rales et d√©mographiques ainsi que des informations pr√©cises sur la phase du CPRCm et ses traitements ont √©t√© collig√©es √† partir des dossiers m√©dicaux des patients jusqu‚Äôau 10 mai 2016. La cohorte √† l‚Äô√©tude a √©t√© divis√©e en deux groupes selon la p√©riode de diagnostic du CPRCm. La date de l‚Äôajout de l‚Äôabiraterone (et du d√©nosumab) √† la liste de m√©dicaments d‚Äôexception rembours√©s par le r√©gime g√©n√©ral d‚Äôassurance m√©dicaments du Qu√©bec (le 1e f√©vrier 2012) a √©t√© utilis√©e comme date de coupure. Des statistiques descriptives ont √©t√© utilis√©es pour d√©crire l‚Äôutilisation du docetaxel, de l‚Äôabiraterone, de l‚Äôenzaluatamide, du d√©nosumab et de l‚Äôacide zol√©dronique. La m√©thode de Kaplan-Meier et le test du Logrank ont √©t√© utilis√©s pour estimer le temps jusqu‚Äô√† avoir une premi√®re ordonnance du docetaxel et des th√©rapies osseuses. Par ailleurs, la r√©gression multivari√©e de Cox a permis d‚Äôidentifier les d√©terminants de l‚Äôusage du docetaxel, de l‚Äôabiraterone (ou de l‚Äôenzalutamide) et des th√©rapies osseuses.
R√©sultats : Dans notre cohorte, 308 patients atteints du CPRCm ont √©t√© s√©lectionn√©s avec 162 patients (53 %) diagnostiqu√©s avec le CPRCm avant le 1e f√©vrier 2012 et 146 patients (47 %) diagnostiqu√©s avec le CPRCm apr√®s le 1e f√©vrier 2012. L‚Äô√¢ge
ii
m√©dian au diagnostic du CPRCm √©tait de 74,0 ans. Globalement, 82 % des patients diagnostiqu√©s avant 2012 ont eu docetaxel, 53 % ont eu abiraterone et 54% ont eu abiraterone ou enzalutamide comparativement √† 53 %, 74 % et 86 %, respectivement, de ceux diagnostiqu√©s apr√®s 2012. Les d√©terminants de l‚Äôusage global du docetaxel √©taient la pr√©sence de m√©tastases (osseuses et ganglionnaires, et visc√©rales) au diagnostic du CPRC, la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm, avoir moins que 80 ans au diagnostic du CPRCm, √™tre diagnostiqu√© avec le CPRCm avant 2012 et √™tre symptomatique au diagnostic du CPRCm. Les d√©terminants de l‚Äôusage de l‚Äôabiraterone (ou de l‚Äôenzalutamide) √©taient la pr√©sence de m√©tastases (osseuses, ganglionnaires, et visc√©rales) au diagnostic du CPRC, la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm, avoir plus que 80 ans au diagnostic du CPRCm, √™tre diagnostiqu√© avec le CPRCm apr√®s 2012 et avoir des comorbidit√©s cardiaques ou chroniques au diagnostic du CPRCm. Le temps m√©dian avant une premi√®re ordonnance du docetaxel √©tait retard√© de six mois chez les patients diagnostiqu√©s apr√®s 2012 par rapport √† ceux diagnostiqu√©s avant 2012 (p=0,0001). Parmi les patients ayant des m√©tastases osseuses, 82 % ont eu au moins une ordonnance d‚Äôune th√©rapie osseuse (le d√©nosumab ou l‚Äôacide zol√©dronique). Les d√©terminants de l‚Äôusage des th√©rapies osseuses √©taient d‚Äôavoir des m√©tastases osseuses, d‚Äô√™tre diagnostiqu√© avec le CPRCm apr√®s 2012 et d‚Äô√™tre symptomatique au diagnostic du CPRCm.
Conclusion : L‚Äôintroduction de abiraterone (et de l‚Äôenzalutamide) a r√©duit l‚Äôutilisation globale du docetaxel et a prolong√© le temps jusqu‚Äô√† recevoir une ordonnance de celui-ci. Les d√©terminants de l‚Äôusage de ces traitements √©taient l‚Äô√©tendue des m√©tastases, l‚Äô√¢ge au diagnostic du CPRCm, la p√©riode du diagnostic du CPRCm et la r√©f√©rence √† un oncologue avant le d√©veloppement du CPRCm. Par ailleurs, une proportion significative des patients avec un CPRCm a re√ßu une ordonnance d‚Äôune th√©rapie osseuse.</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dcterms.abstract</td><td class="word-break">Introduction: Since 2004, docetaxel-based chemotherapy has been the cornerstone of the management of metastatic castration-resistant prostate cancer (mCRPC). The therapeutic arsenal expanded in 2011 to involve several alternative drugs such as abiraterone and enzalutamide for use in docetaxel-refractory patients and then in docetaxel-na√Øve ones (since 2013). This study aimed to describe docetaxel, abiraterone (and enzalutamide) use and its associated factors in Quebec. It also aimed to describe bone-targeted therapy (denosumab and zoledronic acid) utilization and its associated factors in mCRPC patients. Methods: A retrospective cohort study was conducted in two of the main McGill University hospitals. Hospital-based cancer registries were used to identify patients treated for prostate cancer in medical oncology departments between January 1, 2010 and June 30, 2014. Then patients with mCRPC were selected. Patients‚Äô medical charts were reviewed and mCRPC clinical data and treatments were extracted until May 10, 2016. The cohort was divided into two groups according to mCRPC diagnosis period. The cutoff date chosen was February 1, 2012 as it corresponded to the public reimbursement of abiraterone (and denosumab) in Quebec. Descriptive statistics were used to describe docetaxel, abiraterone, enzalutamide, and bone-targeted therapy (denosumab and zoledronic acid) utilization. The Kaplan-Meier method and log-rank test were used to estimate time to receive a first prescription for docetaxel and bone-targeted therapy since mCRPC diagnosis. Cox regression was used to identify predictive factors of docetaxel, abiraterone (or enzalutamide), and bone-targeted therapy use. Results: In our cohort, 308 patients with mCRPC were selected with 162 patients (53%) diagnosed with mCRPC before February 1, 2012 (pre-2012 group) and 146 (47%) diagnosed with mCRPC after February 1, 2012 (post-2012 group). The median age at mCRPC was 74.0 years old. In the pre-2012 group, patients received following treatments: docetaxel 82%, abiraterone 53%, and abiraterone or enzalutamide 54% versus 53%, 74% and 86%, respectively, in the post-2012 group. Factors associated with docetaxel use were having metastases (bone and lymph nodes, and visceral) at CRPC diagnosis, referral to an oncologist before mCRPC development, being younger than 80 at mCRPC diagnosis, having symptoms at mCRPC diagnosis and being diagnosed with mCRPC before 2012. Factors associated with abiraterone (or enzalutamide) use were having metastases (bone, lymph nodes, and visceral) at CRPC diagnosis, referral to an oncologist before mCRPC development, being older than 80 at mCRPC diagnosis, having cardiac or chronic comorbidites at mCRPC diagnosis and being diagnosed with mCRPC after 2012. The median time to have a prescription for docetaxel was delayed by six months in patients diagnosed after 2012 comparatively to those diagnosed before 2012 (p=0.0001). Among patients with bone metastases, 82% had at least one prescription for a bone-targeted therapy (denosumab or zoledronic acid). Factors associated with bone-targeted therapy use were having bone metastases at CRPC diagnosis, being diagnosed with mCRPC after 2012 and having symptoms at mCRPC diagnosis.
Conclusion: The introduction of abiraterone (and enzalutamide) reduced overall docetaxel utilization and delayed time to its initiation. Metastases extent, age, moment of diagnosis with mCRPC, and referral to an oncologist before mCRPC development were the predictive factors either docetaxel, abiraterone or enzalutamide utilization. Patients with mCRPC benefit from bone-targeted therapy (denosumab or zoledronic acid) for bone metastases.</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dcterms.language</td><td class="word-break">fra</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">UdeM.ORCIDAuteurThese</td><td class="word-break">0000-0002-7276-2739</td><td>fr</td>
</tr>
</table>
</div>
<span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&amp;rft_id=http%3A%2F%2Fhdl.handle.net%2F1866%2F19454&amp;rfr_id=info%3Asid%2Fdspace.org%3Arepository&amp;rft.degree=Sciences+pharmaceutiques&amp;rft.degree=Universit%C3%A9+de+Montr%C3%A9al&amp;rft.degree=Ma%C3%AEtrise+%2F+Master%27s&amp;rft.degree=M.+Sc."> Ôªø 
        </span>
<h3>Files in this item</h3>
<div class="file-list">
<div class="file-wrapper row">
<div class="col-xs-6 col-sm-3">
<div class="thumbnail-wrapper">
<a href="/xmlui/bitstream/handle/1866/19454/Lahcene_Halima_2017_memoire.pdf?sequence=2&amp;isAllowed=y"><img alt="PDF" class="thumbnail-papyrus thumbnail_icone" height="122" src="/xmlui/themes/Mirage2/images/mimes/mime_pdf.png" style="height: 122px;" title="PDF" width="92"/></a>
</div>
</div>
<div class="col-xs-6 col-sm-7">
<dl class="file-metadata dl-horizontal">
<dt>Name:</dt>
<dd class="word-break" title="Lahcene_Halima_2017_memoire.pdf">
<a href="/xmlui/bitstream/handle/1866/19454/Lahcene_Halima_2017_memoire.pdf?sequence=2&amp;isAllowed=y">Lahcene_Halima_2017_memoire.pdf</a>
</dd>
<dt>Size:</dt>
<dd class="word-break">2.495Mb</dd>
<dt>Format:</dt>
<dd class="word-break">PDF</dd>
<dt>Description:</dt>
<dd class="word-break" title="M√©moire">M√©moire</dd>
</dl>
<div>
<span class="bold embargo"><span class="dateembargo">Under embargo</span>¬†until: </span> <span class="embargo dateembargo">2022-10-03</span>
<div class="btn_request_a_copy">
<a class="btn_request_a_copy" href="/xmlui/bitstream/handle/1866/19454/Lahcene_Halima_2017_memoire.pdf?sequence=2&amp;isAllowed=y">üîì Request copy</a>
</div>
</div>
</div>
</div>
</div>
<h3 class="ds-list-head">This item appears in the following Collection(s)</h3>
<ul class="ds-referenceSet-list">
<!-- External Metadata URL: cocoon://metadata/handle/1866/2621/mets.xml-->
<li>
<a href="/xmlui/handle/1866/2621">Th√®ses et m√©moires √©lectroniques de l‚ÄôUniversit√© de Montr√©al</a> [18270]<br/>
</li>
<!-- External Metadata URL: cocoon://metadata/handle/1866/2969/mets.xml-->
<li>
<a href="/xmlui/handle/1866/2969">Facult√© de pharmacie ‚Äì Th√®ses et m√©moires</a> [388]<br/>
</li>
</ul>
<p class="ds-paragraph item-view-toggle item-view-toggle-bottom">
<span class="item-view-toggle"><a href="/xmlui/handle/1866/19454">Show item record</a></span>
</p>
</div>
</div>
<div class="visible-xs visible-sm">
<footer>
<div class="row">
<hr/>
<div class="col-xs-7 col-sm-8">
<div>
<a href="http://www.dspace.org/" target="_blank">DSpace software</a>
                        [version 5.8 XMLUI],
                        copyright¬†¬©¬†2002-2015¬† <a href="http://www.duraspace.org/" target="_blank">DuraSpace</a>
</div>
<div class="hidden-print">
<a href="/xmlui/contact">Contact Us</a> | <a href="/xmlui/feedback">Send Feedback</a>
</div>
</div>
<div class="col-xs-5 col-sm-4 hidden-print">
<div class="pull-right">
<script type="text/javascript"> 
										      (function(d, t) { 
										        var s = d.createElement(t), options = {'domain':'papyrus.bib.umontreal.ca','style': '16','container':'entrust-net-seal'}; 
										        s.src = 'https://seal.entrust.net/sealv2.js'; 
										        s.async = true; 
										        var scr = d.getElementsByTagName(t)[0], par = scr.parentNode; par.insertBefore(s, scr); 
										        s.onload = s.onreadystatechange = function() { 
										        var rs = this.readyState; if (rs) if (rs != 'complete') if (rs != 'loaded') return; 
										        try{goEntrust(options)} catch (e) {} }; 
										        })(document, 'script'); 
										</script>
<div id="entrust-net-seal">
<a href="https://www.entrust.com/ssl-certificates/">Certificat SSL / SSL Certificate</a>
</div>
</div>
</div>
</div>
<div class="row bib-footer hidden-print">
<div class="col-xs-12 col-sm-12 col-md-4">
<a class="footerEXLlink" href="http://www.bib.umontreal.ca"><img alt="les biblioth√®ques/UdeM" src="/xmlui/themes/Mirage2/images/propulse-par.png"/></a>
</div>
<div class="hidden-xs col-sm-12 col-md-8">
<nav>
<ul>
<li>
<a href="https://www.urgence.umontreal.ca/">Emergency</a>
</li>
<li>
<a href="http://www.carrieres.umontreal.ca/">Careers</a>
</li>
<li>
<a href="https://outlook.umontreal.ca/">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
<li>
<a href="http://itunesu.umontreal.ca/">iTunes U</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/a-propos/nous-ecrire.htm">Contact us</a>
</li>
<li>
<a href="https://www.facebook.com/bibUdeM"><img alt="Facebook" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Facebook.png"/></a>
</li>
<li>
<a href="https://www.youtube.com/user/BibliothequesUdeM"><img alt="YouTube" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-YouTube.png"/></a>
</li>
<li>
<a href="https://twitter.com/bibUdeM"><img alt="Twitter" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Twitter.png"/></a>
</li>
<li>
<a href="https://www.nouvelles.umontreal.ca/frontpage/rss.html"><img alt="University RSS" src="/xmlui/themes/Mirage2/images/bib-umontreal/icone-syndication-14x14.png"/></a>
</li>
</ul>
</nav>
</div>
</div>
<a class="hidden" href="/xmlui/htmlmap">¬†</a>
<p>¬†</p>
</footer>
</div>
</div>
</div>
</div>
<div class="hidden-xs hidden-sm">
<footer>
<div class="row">
<hr/>
<div class="col-xs-7 col-sm-8">
<div>
<a href="http://www.dspace.org/" target="_blank">DSpace software</a>
                        [version 5.8 XMLUI],
                        copyright¬†¬©¬†2002-2015¬† <a href="http://www.duraspace.org/" target="_blank">DuraSpace</a>
</div>
<div class="hidden-print">
<a href="/xmlui/contact">Contact Us</a> | <a href="/xmlui/feedback">Send Feedback</a>
</div>
</div>
<div class="col-xs-5 col-sm-4 hidden-print">
<div class="pull-right">
<script type="text/javascript"> 
										      (function(d, t) { 
										        var s = d.createElement(t), options = {'domain':'papyrus.bib.umontreal.ca','style': '16','container':'entrust-net-seal'}; 
										        s.src = 'https://seal.entrust.net/sealv2.js'; 
										        s.async = true; 
										        var scr = d.getElementsByTagName(t)[0], par = scr.parentNode; par.insertBefore(s, scr); 
										        s.onload = s.onreadystatechange = function() { 
										        var rs = this.readyState; if (rs) if (rs != 'complete') if (rs != 'loaded') return; 
										        try{goEntrust(options)} catch (e) {} }; 
										        })(document, 'script'); 
										</script>
<div id="entrust-net-seal">
<a href="https://www.entrust.com/ssl-certificates/">Certificat SSL / SSL Certificate</a>
</div>
</div>
</div>
</div>
<div class="row bib-footer hidden-print">
<div class="col-xs-12 col-sm-12 col-md-4">
<a class="footerEXLlink" href="http://www.bib.umontreal.ca"><img alt="les biblioth√®ques/UdeM" src="/xmlui/themes/Mirage2/images/propulse-par.png"/></a>
</div>
<div class="hidden-xs col-sm-12 col-md-8">
<nav>
<ul>
<li>
<a href="https://www.urgence.umontreal.ca/">Emergency</a>
</li>
<li>
<a href="http://www.carrieres.umontreal.ca/">Careers</a>
</li>
<li>
<a href="https://outlook.umontreal.ca/">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
<li>
<a href="http://itunesu.umontreal.ca/">iTunes U</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/a-propos/nous-ecrire.htm">Contact us</a>
</li>
<li>
<a href="https://www.facebook.com/bibUdeM"><img alt="Facebook" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Facebook.png"/></a>
</li>
<li>
<a href="https://www.youtube.com/user/BibliothequesUdeM"><img alt="YouTube" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-YouTube.png"/></a>
</li>
<li>
<a href="https://twitter.com/bibUdeM"><img alt="Twitter" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Twitter.png"/></a>
</li>
<li>
<a href="https://www.nouvelles.umontreal.ca/frontpage/rss.html"><img alt="University RSS" src="/xmlui/themes/Mirage2/images/bib-umontreal/icone-syndication-14x14.png"/></a>
</li>
</ul>
</nav>
</div>
</div>
<a class="hidden" href="/xmlui/htmlmap">¬†</a>
<p>¬†</p>
</footer>
</div>
</div>
<script src="https://www.google.com/jsapi">¬†</script><script>if(!window.DSpace){window.DSpace={};}window.DSpace.context_path='/xmlui';window.DSpace.theme_path='/xmlui/themes/Mirage2/';</script><script src="/xmlui/themes/Mirage2/scripts/theme.js">¬†</script><script>
                  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
                  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
                  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
                  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

                  ga('create', 'UA-305727-1', 'papyrus.bib.umontreal.ca');
                  ga('send', 'pageview');
           </script><script>         
             var details_Papyrus =  $("#aspect_viewArtifacts_Navigation_list_account .details_Papyrus").text();
             $("#aspect_viewArtifacts_Navigation_list_account a[href='/xmlui/login']").attr("title",details_Papyrus);
        </script>
</body></html>
